United States Biologics Market Projected to Expand at 7.1% CAGR, Reaching USD 966.98 billion by 2033 | Led by Johnson & Johnson, Roche Holding AG, AbbVie Inc.

The global Biologics Market reached USD 512.25 billion in 2024 and is projected to reach USD 966.98 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033, according to DataM Intelligence.

United States: Recent Industry Developments

✅ In October 2025, Johnson & Johnson received FDA approval for its novel interleukin inhibitor for treating moderate-to-severe psoriasis.
✅ In October 2025, The Centers for Medicare & Medicaid Services expanded coverage for biosimilars, increasing patient access to affordable biologic therapies.
✅ In October 2025, A US-based biotech company launched the first subcutaneous formulation of a blockbuster monoclonal antibody, improving patient convenience.

Japan: Recent Industry Developments

✅ In October 2025, Takeda Pharmaceutical introduced a new biologic for rare blood disorders, receiving fast-track approval from Japan's PMDA.
✅ In October 2025, Japan's Ministry of Health implemented new guidelines to accelerate the approval process for biosimilar products.
✅ In October 2025, A consortium of Japanese research institutes developed a novel platform for producing complex biologics using plant-based systems.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/biologics-market?jd

Market Trends & Drivers

The Biologics Market is experiencing unprecedented growth driven by advancements in biotechnology, increasing prevalence of chronic diseases, and rising demand for targeted therapies. Key trends include the expansion of biosimilars, development of novel antibody-drug conjugates, and increased investment in cell and gene therapies. The growing focus on personalized medicine, orphan drug designations, and technological innovations in manufacturing processes are significantly accelerating market expansion across therapeutic areas.

Competitive Landscape

The market is dominated by pharmaceutical giants with strong biologics pipelines and manufacturing capabilities.

Johnson & Johnson leads with a diverse biologics portfolio including immunology, oncology, and neuroscience products.
Roche Holding AG maintains a strong position with its extensive monoclonal antibody pipeline and biosimilar developments.
AbbVie Inc. specializes in immunology biologics with blockbuster products and ongoing pipeline innovation.
Novartis AG advances biologics development through its specialized divisions and gene therapy platforms.
Pfizer Inc. expands its biologics presence through strategic acquisitions and internal R&D programs.
Amgen Inc. pioneers biologics development with focus on oncology, cardiovascular, and inflammatory diseases.
Bristol-Myers Squibb Company strengthens its biologics portfolio through immunotherapy and targeted therapy innovations.
Merck & Co., Inc. develops innovative biologics for oncology and infectious disease applications.
Sanofi S.A. focuses on biologics for immunology, rare diseases, and vaccine development.
Eli Lilly and Company advances biologics research with focus on diabetes, oncology, and immunology.

Segmentation

By Product Type (Monoclonal Antibodies (mAbs), Vaccines, Recombinant Hormones/Proteins, Cell Therapy, Gene Therapy, Antisense & RNAi Therapeutics, Others)
By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders, Others)
By Manufacturing (In-house Manufacturing, Outsourced/Contract Manufacturing)
By End-User (Pharmaceutical and Biotechnology Companies, Hospitals, Research & Academic Institutes, Others)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biologics-market?jd

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.

This release was published on openPR.